Russian watchdog suspects Bristol-Myers of cartel activities in state tenders last year

3 October 2018

Bristol-Myers Squibb (NYSE: BMY) had participated in a cartel agreement during the conduct of state tenders for the purchases of drugs for state needs last year, according to recent statements by a head of the FAS’ department for the fight against cartels Andrei Tenishev, reports The Pharma Letter’s local correspondent.

Mr Tenishev said last week that the FAS started its investigation, regarding with B-MS’ participation in a possible cartel agreement in the Russian pharmaceutical market, which may last up to three months.

According to him, the regulator has already copied all the needed documents and correspondence which are needed for investigation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK